Interleukin-10 promoter polymorphisms in hepatitis C patients with and without Schistosoma mansoni co-infection

Liver International

Volumn 29, Issue 9, 2009, Pages 1422-1430

  Abbas, Omaima M ^a   Abdel Rahman, Mohamed H ^a   Omar, Nabil A ^b   Badran, Hanaa M ^b   Amir, Elamir M ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Hepatitis C; IL 10; polymorphisms; schistosomiasis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GENOMIC DNA; INTERLEUKIN 10; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; AGE; AGED; ARTICLE; BLOOD ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROMOTER REGION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SEX DIFFERENCE; TREATMENT OUTCOME; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SCHISTOSOMIASIS MANSONI;

EID: 70449707798     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02068.x     Document Type: Article

References (63)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
2. Strickland G.T. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006; 43: 915-22.
3. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000; 32(Suppl.): 98-112.
4. Lasarte JJ, García-Granero M, López A, et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 1998; 28: 815-22.
5. Ferrari C, Valli A, Galati L, et al. T-cell response to structural and nonstructural hepatitis C variants in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19: 286-95.
6. Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(1) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002; 195: 603-16.
7. Hussain MJ, Botta S, Pensati L, et al. Cytokine profile defines different responses to interferon-a treatment in chronic hepatitis C infection. Hepatology 1998; 28: 273A.
8. Sher A, Gazzinelli RT, Oswald IP, et al. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev 1992; 127: 183-204.
9. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(1) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933-41.
10. Zhang LJ, Wang X.Z. Interleukin-10 and chronic liver disease. World J Gastroenterol 2006; 12: 1681-5.
11. Isaguliants MG, Ozeretskovskaya N.N. Host background factors contributing to hepatitis C virus clearance. Curr Pharm Biotechnol 2003; 4: 185-93.
12. Kamal SM, El Sayed Khalifa K. Immune modulation by helminthic infections: worms and viral infections. Parasite Immunol 2006; 28: 483-96.
13. AbelM, Seńe D, Pol S, et al. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology 2006; 44: 1607-16.
14. Darwish MA, Raouf TA, Rushdy P, et al. Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. Am J Trop Med Hyg 1993; 49: 440-7.
15. Ghaffar YA, Fattah SA, Kamel M, et al. The impact of endemic schistosomiasis on acute viral hepatitis. Am J Trop Med Hyg 1991; 45: 743-50.
16. Kullberg MC, Pearce EJ, Hieny SE, Sher A, Berzofsky J.A. Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen. J Immunol 1992; 148: 3264-70.
17. Actor JK, Shirai M, Kullberg MC, et al. Helminth infection results in decreased virus-specific CD81 cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc Natl Acad Sci USA 1993; 90: 948-52.
18. Actor JK, Marshall MA, Eltoum IA, et al. Increased susceptibility of mice infected with Schistosoma mansoni to recombinant vaccinia virus: association of viral persistence with egg granuloma formation. Eur J Immunol 1994; 24: 3050-6.
19. van den Biggelaar AH, van Ree R, Rodrigues LC, et al. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet 2000; 356: 1723-7.
20. Hoffmann KF, Cheever AW, Wynn T.A. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol 2000; 164: 6406-16.
21. Selzner N, Chen L, Borozan I, et al. Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients. J Hepatol 2008; 48: 708-13.
22. Morgan TR, Lambrecht RW, HALT-C Trial Group, et al. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol 2008; 49: 548-56.
23. Chen TY, Hsieh YS, Wu TT, et al. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res 2007; 150: 116-21.
24. Dai CY, Chuang WL, Chang WY, et al. Tumor necrosis factor-alpha promoter polymorphism at position (308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2006; 193: 98-101.
25. Knapp S, Hennig BJ, Frodsham AJ, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003; 55: 362-9.
26. Lio D, Caruso C, Di Stefano R, et al. IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol 2003; 64: 674-80.
27. Mangia A, Santoro R, Piattelli M, et al. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine 2004; 25: 103-9.
28. Vidigal PG, Germer JJ, Zein N.N. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002; 36: 271-7.
29. Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30: 526-30.
30. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
31. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell D.P. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000; 1: 185-90.
32. Hoffmann SC, Stanley EM, Cox ED, et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002; 2: 560-7.
33. Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513-20.
34. Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenac J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000; 32: 172-4.
35. Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004; 103: 3529-34.
36. Hoffmann SC, Stanley EM, Darrin Cox E, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001; 72: 1444-50.
37. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Gawronska-Szklarz B. Association of cytokine gene polymorphisms and the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Int Immunopharmacol 2006; 6: 351-7.
38. Rosenwasser LJ, Borish L. Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10). Am J Respir Crit Care Med 1997; 156(Part 2): S152-5.
39. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
40. Höhler T, Kruger A, Gerken G, et al. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998; 54: 173-7.
41. Zein NN, Germer JJ, El-Zayadi AR, Vidigal P.G. Ethnic differences in polymorphisms of tumor necrosis factoralpha, interleukin-10, and transforming growth factor-beta 1 genes in patients with chronic hepatitis C virus infection. Am J Trop Med Hyg 2004; 70: 434-7.
42. Chuang JY, Yang SS, Lu YT, et al. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis 2009; 41: 424-30.
43. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759-65.
44. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449-58.
45. Bouzgarrou N, Hassen E, Farhat K, et al. Combined analysis of interferon-g and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol 2009; 70: 230-6.
46. Persico M, Capasso M, Persico E, et al. TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis. J Hepatol 2006; 44(Suppl. 2): S165.
47. Abbas Z, Moatter T, Hussainy A, Jafri W. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 2005; 11: 6656-61.
48. AbbottWG, Rigopoulou E, Haigh P, et al. Single nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence chronic hepatitis C severity or Tcell reactivity to hepatitis C virus. Liver Int 2004; 24: 90-7.
49. Yee LJ, Tang J, Gibson AW, et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33: 708-12.
50. Constantini PK, Wawrzynowicz-Syczewska M, Clare M, et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002; 22: 404-12.
51. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Intervetional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
52. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
53. Brouwer JT, Hansen BE, Niesters HG, Schalm S.W. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus A.L.T. J Hepatol 1999; 30: 192-8.
54. Reuss E, Fimmers R, Kruger A, et al. Differential regulation of interleukin-10 production by genetic and environmental factors-a twin study. Genes Immun 2002; 3: 407-13.
55. Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30: 376-82.
56. Cramp ME, Rossol S, Chokshi S, et al. Hepatitis C virusspecific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.
57. Farid A, Al-Sherbiny M, Osman A, et al. Schistosoma infection inhibits cellular immune responses to core HCV peptides. Parasite Immunol 2005; 27: 189-96.
58. Kamal SM, Nasser I.A. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008; 47: 1371-83.
59. Derbala MF, Al Kaabi SR, El Dweik NZ, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12: 5692-8.
60. el-Zayadi A, Selim O, Haddad S, et al. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital J Gastroenterol Hepatol 1999; 31: 472-5.
61. Kamal S.M. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int 2009; 29(Suppl. 1): 39-48.
62. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-9.
63. Elrefaei M, El-sheikh N, Kamal K, Cao H. Analysis of T cell responses against hepatitis C virus genotype 4 in Egypt. J Hepatol 2004; 40: 313-8.